Investigating ways to prevent and treat transformation in chronic myelogenous leukemia and myeloproliferative neoplasms.
Official title: Targeting Immune Escape in CML/MPN Transformation
Funded at Beckman Research Institute/city of Hope · NIH-10997424 · Data updated 2026-11-12
This study is looking at how chronic myelogenous leukemia (CML) and certain blood disorders can become more serious, and it's trying to find new ways to treat these conditions so that patients can have better outcomes and feel healthier.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | December 8, 2023 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $571,615 |
| NIH project number | 5R01CA286160-02 |
| Project ID | NIH-10997424 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with chronic myelogenous leukemia or myeloproliferative neoplasms, particularly those at risk of transformation to more aggressive forms.
✕Less likely to help
Patients with other types of leukemia or those who are not diagnosed with CML or MPN may not benefit from this research.
What this research studies
This research focuses on understanding how chronic myelogenous leukemia (CML) and myeloproliferative neoplasms (MPN) can transform into more aggressive forms, such as blast crisis and secondary acute myeloid leukemia. The team is exploring both intrinsic factors within leukemia stem cells and extrinsic factors from the bone marrow environment that contribute to this transformation. By identifying new therapeutic targets, the goal is to develop treatments that can effectively eliminate leukemia stem cells and restore immune function against the disease. Patients may benefit from novel therapies that arise from this research, potentially improving their outcomes.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively prevent or reverse the transformation of CML and MPN, improving survival rates for patients.
How similar studies have gone: Previous research has shown promise in targeting immune escape mechanisms in leukemia, suggesting that this approach may lead to significant advancements in treatment.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Zhang, Bin — Beckman Research Institute/city of Hope
- Study coordinator: Zhang, Bin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.